What should you know about olaparib brca negative ovarian cancer?

BRCA testing can refer to an inherited change or a change found in tumour tissue, and those tests do not answer exactly the same question. A negative inherited BRCA result does not rule out every DNA-repair change in the tumour. Genomic tumour profiling may identify other features that help the specialist assess whether a PARP inhibitor such as olaparib has a role.

The decision also depends on ovarian cancer type and stage, previous surgery or chemotherapy, response to treatment and other medical conditions. Olaparib is taken by mouth and can cause nausea, tiredness, appetite changes, diarrhoea, headache or low blood counts. Regular blood tests and medication reviews support safer treatment decisions.

Ask which BRCA test was negative, whether tumour profiling has been completed and whether another DNA-repair finding is relevant. Request an explanation of what the result means for your own family as well as for treatment; inherited testing can have implications for relatives. Keep a current medicine list, follow the prescribed schedule and report side effects early. Surgery, chemotherapy and symptom-focused care may remain part of the overall plan.

Contact the oncology team promptly for fever, chills, unusual bruising or bleeding, severe weakness, breathlessness, persistent vomiting, diarrhoea or difficulty drinking. Seek urgent care for fainting, confusion, chest pain, severe breathing difficulty or bleeding that continues. Do not stop olaparib or restart it after an interruption without advice, because the team may need to check blood counts or another cause of the symptom.

Was my negative BRCA result from inherited testing, tumour testing, or both? Should genomic tumour profiling be reviewed? Could another DNA-repair finding affect olaparib? How will you monitor blood counts? Which symptoms require a same-day call? What other treatments could be used if olaparib is unsuitable or not tolerated?